While GLP-1 and GLP-1/GIP medications are generally considered cost-effective for treating obesity in targeted populations [65–67], alternative strategies—such as expanding bariatric surgery access, enhancing lifestyle intervention programmes, pharmaceutical management of cardiometabolic comorbidities, or population-level policies—should also be considered. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.